📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: 89bio

1.1 - Company Overview

89bio Logo

89bio

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of biologic and small molecule therapies for liver and metabolic disorders, developing pegozafermin for MASH to reduce liver fibrosis and for severe hypertriglyceridemia to lower triglyceride levels and address lipid metabolism imbalance.

Products and services

  • Biologic and small molecule treatment pipeline: 89Bio architects a biologic-and-small-molecule pipeline targeting liver and metabolic disorders, producing therapeutics expressly oriented to these indications
  • Pegozafermin for MASH: 89Bio develops pegozafermin (in-development) to treat metabolic dysfunction-associated steatohepatitis, focusing on reducing liver fibrosis and advancing liver-health outcomes in this chronic condition
  • Pegozafermin for SHTG: 89Bio evaluates pegozafermin (evaluation-stage) for severe hypertriglyceridemia to reduce triglyceride levels and address lipid metabolism imbalance in affected populations

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to 89bio

InteKrin Therapeutics Logo

InteKrin Therapeutics

HQ: United States Website
  • Description: Provider of clinical-stage biopharmaceutical development and commercialization of breakthrough therapeutics targeting neuroendocrine, metabolic, and immune disorders, addressing diseases such as diabetes, metabolic syndrome, and cancer.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full InteKrin Therapeutics company profile →
Biocrates Logo

Biocrates

HQ: Austria Website
  • Description: Provider of metabolomics platforms for biomarker discovery and validation in complex diseases. Offers the MxP Quant 500 XL kit for profiling >1,000 compounds, WebIDQ software, MetaboINDICATOR, and data interpretation and statistical analysis services, alongside automated sample preparation integrated with mass-spectrometric methods.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Biocrates company profile →
Nexus BioPharma Logo

Nexus BioPharma

HQ: United States Website
  • Description: Provider of preclinical-stage biotechnology research and development focused on developing new therapies and intellectual property.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Nexus BioPharma company profile →
Tramontane Therapeutics Logo

Tramontane Therapeutics

HQ: Spain Website
  • Description: Provider of gene therapy solutions for common neurological and metabolic illnesses.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Tramontane Therapeutics company profile →
Viking Therapeutics Logo

Viking Therapeutics

HQ: United States Website
  • Description: Provider of novel therapeutics in development targeting metabolic and endocrine disorders, including oral TRβ agonists (VK2809 for lipid/metabolic disorders incl. NASH; VK0214 for X-ALD), a dual GLP-1/GIP agonist (VK2735) for obesity, an oral FBPase inhibitor (VK0612) for type 2 diabetes, a DGAT-1 inhibitor (VK1430) for hypertriglyceridemia/NASH, and an oral non-steroidal SARM (VK5211) for recovery after non-elective hip fracture surgery.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Viking Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for 89bio

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to 89bio

2.2 - Growth funds investing in similar companies to 89bio

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for 89bio

4.2 - Public trading comparable groups for 89bio

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to 89bio

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About 89bio

What does 89bio do?

89bio is a provider of biologic and small molecule therapies for liver and metabolic disorders, developing pegozafermin for MASH to reduce liver fibrosis and for severe hypertriglyceridemia to lower triglyceride levels and address lipid metabolism imbalance.

Who are 89bio's competitors?

89bio's competitors and similar companies include InteKrin Therapeutics, Biocrates, Nexus BioPharma, Tramontane Therapeutics, and Viking Therapeutics.

Where is 89bio headquartered?

89bio is headquartered in United States.

How many employees does 89bio have?

89bio has 1,000 employees 🔒.

When was 89bio founded?

89bio was founded in 2010 🔒.

What sector and industry vertical is 89bio in?

89bio is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for 89bio

Who are the top strategic acquirers in 89bio's sector and industry

Top strategic M&A buyers and acquirers in 89bio's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for 89bio?

Top strategic M&A buyers groups and sectors for 89bio include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in 89bio's sector and industry vertical

Which are the top PE firms investing in 89bio's sector and industry vertical?

Top PE firms investing in 89bio's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in 89bio's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in 89bio's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in 89bio's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to 89bio include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in 89bio's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for 89bio?

The key public trading comparables and valuation benchmarks for 89bio include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for 89bio for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for 89bio with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in 89bio's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for 89bio with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in 89bio's' sector and industry vertical?

Access recent funding rounds and capital raises in 89bio's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for 89bio